Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 915-617-9 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- repeated dose toxicity: oral, other
- Remarks:
- one-generation study
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 007
- Report date:
- 2007
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: OECD Guideline 415 (One-Generation Reproduction Toxicity Study)
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Reference substance name:
- Reaction mass of 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde and 4-(4-hydroxy-4-methylpentyl)cyclohex-3-enecarbaldehyde
- EC Number:
- 915-617-9
- Molecular formula:
- C13H22O2
- IUPAC Name:
- Reaction mass of 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde and 4-(4-hydroxy-4-methylpentyl)cyclohex-3-enecarbaldehyde
- Test material form:
- liquid
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River (UK) Limited, Margate, Kent, UK
- Age at study initiation: (P) males ca. 6 weeks, females ca. 10 weeks
- Weight at study initiation: (P) Males: 191 - 255 g; Females: 211 - 271 g
- Housing: initially, in groups of 4 in polypropylene cages with stainless steel grid floors and tops. During the mating, animals were housed in similar cages on 1:1 male:female basis. After mating males were transferred to the original cages; females were housed individually during gestation and lactation in polypropylene cages with solid floors and stainless steel lids.
- Diet: pelleted diet (Rodent PMI 5002 (certified) diet, ad libitum
- Water: mains drinking water, ad libitum
- Acclimation period: 13 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21 ± 2
- Humidity (%): 55 ± 15
- Air changes (per hr): at least 15/hour
- Photoperiod (hrs dark / hrs light): 12 / 12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- arachis oil
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS
- Formulations were prepared weekly
VEHICLE
- Concentration in vehicle: 0, 6.25, 25 and 125 mg/mL
- Amount of vehicle: 4 mL/kg bw - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The concentration of the test substance in arachis oil was determined by gas chromatography using an external standard technique.
- Duration of treatment / exposure:
- 76 days pre-mating, maximal 21 days mating, males were killed and examined upon evidence of successful mating, females and offspring were killed and examined on day 21 post-partum. Non-pregnant females were killed and examined after day 25 post-coitum.
- Frequency of treatment:
- Daily (except for females during littering/parturition)
Doses / concentrationsopen allclose all
- Dose / conc.:
- 25 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 100 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 500 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 24
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Details on mating procedure
- Age at mating of the mated animals in the study: mating was performed on day 76 of treatment.
- M/F ratio per cage: 1:1
- Length of cohabitation: a maximum of 21 days
- Proof of pregnancy: vaginal plug and/or sperm in vaginal smear referred to as day 1 of pregnancy
- After successful mating each pregnant female was caged individually during gestation and lactation in polypropylene cages with solid floors and stainless steel lids, furnished with softwood flakes
Dose selection rationale: based on the results of a 14-day dose-range finding study
Rationale for animal assignment: the animals were allocated to dose groups using a randomisation procedure based on stratified body weights.
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: the animals were examined for overt signs of toxicity, ill-health and behavioural change immediately before and after the dosing, and 1 and 5 hours post-dosing during the working week. Animals were observed immediately before and after dosing and 1 hour post-dosing at the weekends or public holidays.
BODY WEIGHT: Yes
- Time schedule for examinations: Day 0, then weekly for males until termination. Females were weighed weekly during maturation and daily during mating. Once mating was evident, body weights were recorded on days 1, 4, 7, 14 and 21 of post-coitum and post-partum.
FOOD CONSUMPTION AND COMPOUND INTAKE: yes
- Time schedule for examinations: During the maturation period, weekly food consumption was recorded for each cage. For females showing evidence of mating, food consumption was recorded for the period covering days 1 - 7, 7 - 14 and 14 - 21 post-coitum. For females with live litters, food consumption was recorded for the period covering days 1 - 7, 7 - 14 and 14 - 21 post-partum.
WATER CONSUMPTION AND COMPOUND INTAKE: Yes
- Time schedule for examinations: Water intake was observed daily by visual inspection of water bottles for any overt change.
OTHER:
- During mating, a vaginal smear was prepared for each female daily and the stage of the oestrous cycle was recorded.
- Parameters examined in P male parental generations: testis weight, epididymis weight, numbers of homogenisation resistant spermatids, sperm motility, sperm morphology
- The following parameters were examined in F1 offspring: number and sex of pups, stillbirths, live births, postnatal mortality, presence of gross anomalies, weight gain, physical or behavioural abnormalities, the detachment and unfolding of pinna, incisor eruption and eyelid separation, reflexological response to stimuli by assessing surface righting reflex on Day 1 post-partum and air righting reflex on Day 17 post-partum. Pupillary reflex and auditory startle response were performed on day 21 post-partum. - Sacrifice and pathology:
- SACRIFICE
- Male animals: All surviving animals; after successful mating.
- Maternal animals: All surviving animals; on day 21 post-partum; for non-pregnant females on or after day 25 post-coitum.
- The off-spring was sacrificed on day 21 after birth.
GROSS NECROPSY
- Gross necropsy consisted of full external and internal examinations of parental animals.
HISTOPATHOLOGY / ORGAN WEIGHTS
- The following tissues of parental animals were prepared for microscopic examination and weighed, respectively: cervix, coagulating gland, epididymides, ovaries, pituitary gland, prostate, seminal vesicles, testes, uterus, vagina. - Statistics:
- Linear regression analysis, followed by ANOVA incorporating Levene's test for homogeneity of variance was used for data on organ weights, weekly body weight, litter weights, offspring body weights. Where variances were shown to be homogenous, pairwise comparisons were conducted using Dunnett's test. Where Levene's test showed unequal variances, the data were analysed using non-parametric methods: Kruskal-Wallis ANOVA and Mann-Whitney "U" test.
The non-parametric methods were also used to analyse implantation loss, offspring sex ratio, litter size and landmark developmental markers.
Chi-squared analysis was used for differences in the incidence of lesions occurring with an overall frequency of 1 or greater.
Kruskal-Wallis one-way non-parametric analysis of variance was used for the comparison of severity grades for the more frequently observed graded conditions.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Episodes of hunched posture, pilo-erection and tiptoe gait were evident in 500 mg/kg bw/day females during the final week of gestation.
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- One male treated with 500 mg/kg bw/day was killed in extremis on day 93. One female from this treatment group was found dead on day 97 and a further two females were killed in extremis on days 99 and 100 following difficulties during parturition.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- The body weight gain for parental males of 500 mg/kg bw/day group was generally lower (average -22 %, range -9 % to -43 %) than control animals throughout much of the treatment period, with statistical differences observed in Weeks 4, 5, 6 and 10.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Parental females treated with 500 mg/kg bw/day showed a notable reduction in food consumption (average -21 %, range -17 % to -28 %) throughout lactation, with statistically significant differences throughout 3 weeks.
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no treatment-related effects.
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- The adult male treated with 500 mg/kg bw/day that was killed in extremis showed gaseous distension in the gastro-intestinal tract. The female treated with 500 mg/kg bw/day that was found dead around parturition had 21 foetuses in-utero. The two females from this treatment group that were killed in extremis both had dead/inactive fetuses in-utero and red/brown staining around the anogenital region and dark contents in the stomach or enlarged adrenals and an absent rougae on the non-glandular region of the stomach.
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No treatment-related microscopic changes were observed in the parental animals.
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- maternal toxicity
- Effect level:
- 25 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Based on gestation length increase.
Target system / organ toxicity
- Key result
- Critical effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- In the one-generation study with rats, the NOAEL for parental toxicity was set at 25 mg/kg bw/day, based on gestation length increase in 100 and 500 mg/kg bw.
- Executive summary:
Oral repeated dose toxicity of the test substance was studied in an OECD TG 415 study in compliance GLP using Sprague-Dawley rats. The substance was administered at dose levels of 0, 25, 100 and 500 mg/kg bw/day as a solution in arachis oil to groups of 24 rats/sex/dose for 76 days pre-mating and during maximum 21 days mating, after which males were killed, while females were killed and examined on day 21 post-partum. Females were killed and examined after day 25 post-coitum. One male treated with 500 mg/kg bw/day was killed in extremis on day 93. One female from this treatment group was found dead on day 97 and a further two females were killed in extremis on days 99 and 100 following difficulties during parturition. Episodes of hunched posture, pilo-erection and tiptoe gait were evident in 500 mg/kg bw/day females during the final week of gestation. Body weight gain for males of the 500 mg/kg bw/day group was generally lower (average -22 %, range -9% to -43 %) than control animals throughout much of the treatment period, with statistical differences observed in weeks 4, 5, 6 and 10. Females treated with 500 mg/kg bw/day showed a notable reduction in food consumption (average -21 %, range -17 % to -28 %) throughout lactation, with statistically significant differences throughout 3 weeks. There were no toxicologically significant effects on the concentration,motility or morphology of samples of epididymal sperm. There were no treatment-related effects on the concentration of homogenisation resistant epididymal or testicular spermatid counts. An increased gestation length was observed in the 100 and 500 mg/kg bw dose groups.At necropsy, the adult male treated with 500 mg/kg bw/day that was killed in extremis showed gaseous distension in the gastrointestinal tract. The female treated with 500 mg/kg bw/day that was found dead around parturitionhad 21 foetuses in-utero. The two females from this treatment group that were killed in extremis both had dead/inactive foetuses in-utero and red/brown staining around the ano-genital region and dark contents in the stomach or enlarged adrenals and an absent rougae on the non-glandular region of the stomach. No treatment-related microscopic changes were observed in the parental animals.Based on the observed increased gestation length, the NOAEL for parental toxicity was set at 25 mg/kg bw/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.